trending Market Intelligence /marketintelligence/en/news-insights/trending/ZB4fa_m33C4-gmb_cg16Pw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Kyorin Holdings to develop aTyr Pharma's lung disease drug in Japan

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Kyorin Holdings to develop aTyr Pharma's lung disease drug in Japan

Kyorin Holdings Inc. and aTyr Pharma Inc. signed an agreement to develop aTyr's lung disease drug in Japan.

Under the agreement, Tokyo-based Kyorin Holdings will have exclusive right to develop and commercialize ATYR1923 in Japan.

San Diego-based aTyr, which is developing ATYR1923 to treat interstitial lung diseases, will receive an up-front payment of $8 million.

ATyr may receive up to an additional $167 million if it reaches certain development, regulatory and sales milestones. The company may also receive tiered royalties on net sales in Japan.

Kyorin will fund all research, development, regulatory, marketing and commercialization activities for ATYR1923 in Japan while aTyr will supply the drug.

Interstitial lung diseases cause scarring in lung tissue which may affect a patient's ability to breathe.